News

MassBioDrive Spring 2024: Frequently Asked Questions

With the application now open for MassBioDrive’s spring 2024 cohort, we’ve put together this overview of answers to the most common questions we receive about this program. If you have any additional questions, please don’t hesitate to reach out to our team at drive (at) massbio (dot) org. And, as a reminder,… … […]

News

Brand drug naming faces challenges in emerging categories, expert says

As brand drug naming gets more difficult, some therapy areas like obesity and Alzheimer’s disease are facing even more challenges. That’s because both are traditionally more conservative categories when it comes to the kinds of names the FDA will allow. Hinting at benefits, or even subtle implications, such as weight… … […]

News

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca

NATICK, Mass., Jan. 2, 2024 /PRNewswire/ — Allorion Therapeutics (“Allorion”), a US and China-based biotechnology company that focuses on the discovery of new small molecule drugs for treating cancer and autoimmune diseases, has entered into an exclusive option and global license… … […]

News

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study… … […]